Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people ...
Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® ...
USA-based Endo Inc (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its international ...
Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally Disintegrating ...
We are headquartered at the Empire State Building in New York City and are investigating Endo, Inc. (OTC: NDOI), relating to the proposed merger with Mallinckrodt plc. Under the terms of the ...
The Ademi Firm is investigating Endo (OTCQX: NDOI) for possible breaches of fiduciary duty and other violations of law in its transaction with Mallinckrodt .
MALVERN, Pa., Feb. 17, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of its new branded television commercial, Steve's Journey. The campaign, featuring a real Dupuytren ...
March 13, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today reported financial results for the fourth quarter and full-year ended December 31, 2024. "We ended the year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback